Rajeev Sivasankaran, PhD, vice president of neuroscience at Voyager Therapeutics, discussed preclinical data on the company’s AAV-delivered RNA interference therapy, VY-1706.
Rajeev Sivasankaran, PhD
Advertisement
Articles by Rajeev Sivasankaran, PhD
The vice president of neuroscience at Voyager Therapeutics shared preclinical data on the company’s AAV-delivered RNA interference therapy, VY-1706.
Advertisement
Latest Updated Articles
Rajeev Sivasankaran, PhD, on Voyager’s Single-Dose AAV Strategy for Silencing Tau for Alzheimer DiseasePublished: August 6th 2025 | Updated: August 6th 2025
Advertisement
Advertisement
Trending on CGTlive®
1
Roger Hajjar, MD, on the Commercial Viability of Gene Therapy for Ultra Rare Diseases
2
Capricor Therapeutics Testing DMD Cell Therapy Deramiocel’s Mettle in Phase 3 HOPE-3 Clinical Trial
3
The Importance of Addressing Gene Therapy's Financial Viability in Ultra Rare Diseases
4
